Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur Rev Med Pharmacol Sci ; 26(9): 3100-3108, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35587060

RESUMEN

OBJECTIVE: Gastric cancer (GC) is a heterogeneous disease with molecular diversity between and within tumors; therefore, searching for altered genes within this cancer is mandatory to reach the proper individualized targeted therapy. Expressions of Metallothionein (MT) and p21 are not uniform in various types of cancers and their predictive value in GC is controversial. This study aimed to assess the role of MT and p21 in intestinal-type GC and some of its precursor lesions. MATERIALS AND METHODS: Immunohistochemical staining for MT and p21 was applied on paraffin blocks belonging to 30 GCs and 51 benign gastric lesions/precancerous lesions [33 chronic gastritis and 18 chronic gastritis with gastric intestinal metaplasia (GIM)]; 27 of them were associated with H. pylori infection. RESULTS: MT expression was dramatically increased while p21 expression was dramatically decreased from chronic gastritis to GIM to GC. In precancerous lesions, H. pylori-positive cases had significantly higher MT expression and lower p21 expression compared to H. pylori-negative cases. In GCs, decreased expression of both MT and p21 was associated with high-grade and advanced-stage cancers. CONCLUSIONS: Both MT and p21 may have a role in the development and progression of GC, and both proteins may be useful for selecting targeted therapy for GC patients.


Asunto(s)
Metalotioneína , Lesiones Precancerosas , Neoplasias Gástricas , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/biosíntesis , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patología , Gastritis/metabolismo , Gastritis/microbiología , Gastritis/patología , Infecciones por Helicobacter/metabolismo , Infecciones por Helicobacter/patología , Helicobacter pylori/aislamiento & purificación , Humanos , Metalotioneína/biosíntesis , Metalotioneína/genética , Metaplasia/metabolismo , Metaplasia/patología , Lesiones Precancerosas/metabolismo , Lesiones Precancerosas/microbiología , Lesiones Precancerosas/patología , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/microbiología , Neoplasias Gástricas/patología
2.
Eur Rev Med Pharmacol Sci ; 25(22): 6834-6843, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34859846

RESUMEN

OBJECTIVE: A little is known about the role of miRNA-153 expression in prostate cancer (PCa), in this study we aimed to determine the prognostic value of miRNA-153 and PTEN expression in PCa, by correlating their expression with Gleason patterns, Gleason scores, and Grade groups. PATIENTS AND METHODS:  In situ hybridization for miRNA-153 and immunohistochemical staining for PTEN were applied on microarray sections of 80 PCa, with different Gleason grades, and 20 benign prostate hyperplasia (BPH) cases. RESULTS: We found that miRNA-153 expression was significantly higher and PTEN was significantly lower in PCa compared to BPH. In PCa, high miRNA-153 expression and loss of PTEN expression were associated significantly with higher Gleason patterns, higher Gleason scores, and higher Grade groups. The expression of miRNA-153 showed a significant inverse correlation with PTEN expression. CONCLUSIONS: Increased miRNA-153 expression and lost PTEN expression in PCa may provide information on their role in the progression of this cancer, suggesting that miRNA-153 could affect PTEN directly in prostatic neoplastic and hyperplastic lesions, and therefore miRNA-153 can be considered a new tool to improve the treatment efficacy and prognosis of PCa patients.


Asunto(s)
Adenocarcinoma/genética , Adenocarcinoma/metabolismo , MicroARNs , Fosfohidrolasa PTEN/metabolismo , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/metabolismo , Adenocarcinoma/patología , Anciano , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Próstata/metabolismo , Próstata/patología , Hiperplasia Prostática/genética , Hiperplasia Prostática/metabolismo , Neoplasias de la Próstata/patología
3.
J Helminthol ; 95: e53, 2021 Sep 13.
Artículo en Inglés | MEDLINE | ID: mdl-34515021

RESUMEN

Our work aimed to evaluate the possible effect of Annona muricata (Graviola) leaf extract on Trichinella spiralis in in vitro and in vivo studies. Trichinella spiralis worms were isolated from infected mice and transferred to three culture media - group I (with no drugs), group II (contained Graviola) and group III (contained albendazole) - then they were examined using the electron microscope. In the in vivo study, mice were divided into five groups: GI (infected untreated), GII (prophylactically treated with Graviola for seven days before infection), GIII (infected and treated with Graviola), GIV (infected and treated with albendazole) and GV (infected and treated with a combination of Graviola plus albendazole in half doses). Drug effects were assessed by adults and larvae load beside the histopathological small intestinal and muscular changes. A significant reduction of adult and larval counts occurred in treated groups in comparison to the control group. Histopathologically, marked improvement in the small intestinal and muscular changes was observed in treated groups. Also, massive destruction of the cultured adults' cuticle was detected in both drugs. This study revealed that Graviola leaves have potential activity against trichinellosis, especially in combination with albendazole, and could serve as an adjuvant to anti-trichinellosis drug therapy.


Asunto(s)
Annona , Trichinella spiralis , Triquinelosis , Albendazol/farmacología , Animales , Modelos Animales de Enfermedad , Ratones , Triquinelosis/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA